In summary, our study describes the expression of the TAAs NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric melanoma and adult control cohorts as well as benign nevi, on transcript and on protein level, and addresses one of the prerequisites to consider extension of BNT111 cancer vaccine clinical testing to the pediatric population. This evidence concerns the gene MAGEA3 and melanoma.